Furthermore, contraction force quantification confirmed that DMD fibroblasts impair force generation, whereas Nintedanib treatment restored this function in the F.DMD model, leading to increased force generation (Fig. 5I). The gene discussed is DMD; the disease is Duchenne muscular dystrophy.